ストックスクリーナーアプリを入手
20.16
7.12%
1.34
プレマーケット:
20.16
Urogen Pharma Ltd (URGN) 最新ニュース
UroGen Weighs ENVISION Success And Expanded Loan In Bladder Cancer Push - Yahoo Finance
UroGen: ZUSDURI Poised To Replace TURBT Surgery As SOC In Certain Bladder Cancers - Seeking Alpha
UroGen’s ZUSDURI Data And Reimbursement Progress Shift Risk Reward Profile - simplywall.st
UroGen Pharma at TD Cowen Conference: Strategic Growth and Innovation - Investing.com Australia
UroGen Pharma: ZUSDURI Launch Momentum, Strengthening Balance Sheet, and Path to Profitability Support Buy Rating - TipRanks
NMIBC Market: Strong Pharma Growth Forecast Through 2034 - openPR.com
Urogen Pharma (NASDAQ:URGN) Shares Gap Up Following Earnings Beat - MarketBeat
Oppenheimer raises UroGen Pharma stock price target to $34 on Zusduri sales - Investing.com Australia
UroGen Pharma earnings missed by $0.06, revenue fell short of estimates - Investing.com Australia
UroGen Pharma Ltd. (NASDAQ:URGN) Q4 2025 Earnings Call Transcript - Insider Monkey
UroGen refinances debt with $250M facility at 8.25% rate - Investing.com India
UroGen Pharma Strengthens Balance Sheet, Reports FY25 Results And ZUSDURI Launch Progress - Nasdaq
Urogen Pharma Q4 2025 Earnings Call Transcript - MarketBeat
UroGen Pharma (URGN) Quarterly Loss Narrows To US$0.54 EPS Challenging Bearish Narratives - simplywall.st
Oppenheimer Maintains Outperform on UroGen Pharma Ltd. (URGN) March 2026 - Meyka
UroGen Pharma Ltd (URGN) Q4 2025 Earnings Call Highlights: Stron - GuruFocus
Akin, an Elite Global Law Firm - Akin
Oppenheimer reiterates UroGen Pharma stock rating on strong Zusduri sales - Investing.com Australia
Urogen Pharma (NASDAQ:URGN) Shares Down 13.5%Should You Sell? - MarketBeat
Earnings call transcript: UroGen Pharma Q4 2025 misses EPS and revenue forecasts By Investing.com - Investing.com South Africa
Earnings call transcript: UroGen Pharma Q4 2025 misses EPS and revenue forecasts - Investing.com Nigeria
UroGen Pharma Ltd. (URGN) Q4 2025 Earnings Call Transcript Summary - 富途牛牛
Urogen Pharma Q4 Earnings Call Highlights - MarketBeat
URGN: Analyst Maintains Buy Rating with $33 Target | URGN Stock News - GuruFocus
Urogen Pharma (NASDAQ:URGN) Given Buy Rating at D. Boral Capital - MarketBeat
UroGen (URGN) Q4 2025 Earnings Call Transcript - The Globe and Mail
UroGen Pharma Amends Loan Agreement With Pharmakon Advisors - marketscreener.com
Urogen Pharma Ltd reports results for the quarter ended December 31Earnings Summary - TradingView
Urogen Pharma (URGN) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
UroGen Pharma Q4 Net Loss Narrows, Revenue Rises - marketscreener.com
UroGen reports $15.8M in ZUSDURI sales, refinances debt - Investing.com India
UroGen Pharma (URGN) Secures Amended $250M Loan Agreement - GuruFocus
UroGen Pharma Secures New $250 Million Term Loan - TipRanks
UroGen's (URGN) Revenue Misses Estimates, Eyes Growth with ZUSDU - GuruFocus
UroGen Pharma (URGN) Projects Modest Growth in 2026 Jelmyto Sales - GuruFocus
UROGEN PHARMA ($URGN) Releases Q4 2025 Earnings - Quiver Quantitative
Urogen Pharma (NASDAQ:URGN) Posts Quarterly Earnings Results, Beats Expectations By $0.11 EPS - MarketBeat
UroGen Pharma Ltd. Q4 2025 Earnings Call Summary - Yahoo Finance
UroGen Pharma (URGN) outlines RTGel cancer platform, Jelmyto, Zusduri and pipeline - Stock Titan
UroGen Announces Refinanced Term Loan Agreement with Pharmakon Advisors - The Manila Times
UroGen Pharma (NASDAQ: URGN) inks $250M secured term loan deal - Stock Titan
UroGen Pharma Ltd. Enhances Financial Position with Amended Loan Agreement for Up to $250 Million - Quiver Quantitative
UroGen Announces ZUSDURI™ Launch is On-Track and Reports Fourth Quarter and Full Year 2025 Financial Results - GlobeNewswire
Biotech UroGen lands $200M fixed-rate loan, payments pushed to 2030 - Stock Titan
UroGen Pharma: Q4 Earnings Insights - Sahm
Urogen Pharma (URGN) Projected to Post Quarterly Earnings on Monday - MarketBeat
Urogen Pharma (NASDAQ:URGN) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
A Look At UroGen Pharma (URGN) Valuation After New Phase 3 ENVISION ZUSDURI Data - Yahoo Finance
Trading Systems Reacting to (URGN) Volatility - Stock Traders Daily
UroGen Pharma (URGN) director converts 2,000 RSUs into 2,000 ordinary shares - Stock Titan
UroGen Pharma Earnings Preview - Benzinga
UroGen Pharma Announces EORTC Recurrence Score Analysis of ZUSDURI™ to be Presented at ASCO-GU 2026 - Quiver Quantitative
ZUSDURI™ Achieves Durable Complete Responses Across EORTC - GlobeNewswire
UroGen Pharma Ltd. (URGN) Stock Analysis: A Potential 70% Upside In Biotechnology - DirectorsTalk Interviews
URGNUroGen Announces Refinanced Term Loan Agreement with Pharmakon Advisors - ADVFN Ltd
IPO Launch: Is now the right time to enter UroGen Pharma Ltd2025 Short Interest & Weekly Breakout Watchlists - baoquankhu1.vn
UroGen Pharma Ltd. announced that it expects to receive $250 million in funding - marketscreener.com
UroGen Pharma to Present at the TD Cowen 46th Annual Health Care Conference - The Manila Times
Biotech UroGen Pharma set for TD Cowen talk and 1-on-1 investor meetings - Stock Titan
UroGen Pharma Ltd. to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 2, 2026 - Quiver Quantitative
UroGen Pharma to Report Fourth Quarter and Full-Year 2025 Financial Results on Monday, March 2, 2026 - GlobeNewswire
US Market Wrap: Is UroGen Pharma Ltd a cyclical or defensive stockQuarterly Earnings Summary & Weekly Hot Stock Watchlists - baoquankhu1.vn
NEOS Investment Management LLC Acquires New Position in Urogen Pharma $URGN - MarketBeat
GSA Capital Partners LLP Invests $977,000 in Urogen Pharma $URGN - MarketBeat
UroGen Pharma (URGN) CEO granted 153,195 RSUs in new equity award - Stock Titan
Resistance Check: Is Public Storage stock a top performer YTDJuly 2025 Catalysts & AI Powered Market Entry Strategies - baoquankhu1.vn
How Urogen Pharma Ltd. (URGN) Affects Rotational Strategy Timing - Stock Traders Daily
UroGen Pharma CEO Touts ZUSDURI Launch Momentum, J-Code Boost and Billion-Plus Peak Sales Target - MarketBeat
0.11%
6.00%
大文字化:
|
ボリューム (24 時間):